Amino Acid Metabolism: New Hope for Cholangiocarcinoma
Researchers have uncovered a pivotal role for amino acid metabolism in cholangiocarcinoma, identifying specific pathways that fuel tumor growth. The study highlights glutamine dependence and heightened serine synthesis as metabolic vulnerabilities. Preclinical models show that inhibiting these pathways curtails tumor proliferation, while early-phase clinical trials report extended survival with combination metabolic therapy. These findings suggest a new therapeutic avenue for a cancer with historically limited treatment options.
Hepatokine Fibrinogen-Like Protein 1 Fuels Kidney Fibrosis
Researchers have identified the hepatokine fibrinogen‑like protein 1 (FGL1) as a potent driver of kidney fibrosis. Elevated circulating FGL1 correlated with worsening renal function in mouse models and human chronic kidney disease (CKD) cohorts. Mechanistic studies revealed that FGL1 activates...
Optimizing Coronary Artery Segmentation: Key Design Insights
The Bioengineer roundup highlights five recent studies spanning vaccine durability, metabolic cancer therapy, kidney fibrosis mechanisms, pediatric care experiences, and wearable health sensors. Researchers report that the MVA‑MERS‑S vaccine maintains protective immunity for two years, while amino‑acid metabolism offers a...
Visual Insights: Pediatric Patient and Caregiver Hospital Experiences
Bioengineer.org released a multi‑topic roundup on January 9, 2026 highlighting recent advances across vaccine durability, cancer metabolism, renal disease, cardiovascular imaging, and wearable medical sensors. The MVA‑MERS‑S vaccine demonstrated sustained immunity for two years, while amino‑acid metabolism research offers new therapeutic angles...
Optimizing Culture Conditions for Pure Mycelium Production
The Bioengineer.org portal posted a roundup of cutting‑edge research on January 9, 2026, highlighting innovations ranging from an origami‑inspired smart cushion sensor to AI‑driven digital smile design. It also featured clinical advances such as a two‑year immunity result for the MVA‑MERS‑S vaccine...
Cancer-Selective, Pan-Essential Targets From DepMap
The episode explores a data-driven search for pan‑essential cancer targets—genes whose knockout kills many cancer cell lines but spares normal cells—using the DepMap dataset and Claude‑generated code. It presents the top‑50 selective genes, highlights several promising candidates such as YRDC,...
Organoids Reveal How Pressure and Growth Shape Pancreatic Lumens
Researchers using mouse-derived pancreatic organoids identified three key factors—cell proliferation rate, lumenal pressure, and epithelial permeability—that govern lumen shape during development. They showed that low pressure combined with high proliferation yields star‑shaped, interconnected lumens, while increasing permeability reduces pressure and...
Global Genetic Study Reveals Insights Into Chronic Prostatitis
A multinational genome‑wide association study of chronic prostatitis has been published, encompassing over 200,000 male participants from more than 30 countries. Researchers uncovered 12 previously unknown genetic loci that influence susceptibility, many of which regulate immune signaling and prostate epithelial...
How Merck Plans to Set a Buffer for Keytruda's Patent Cliff
Merck’s blockbuster immunotherapy Keytruda is approaching a major patent cliff, with its primary U.S. patent set to expire in 2028. To blunt the anticipated revenue erosion, the company is deploying a multi‑pronged buffer strategy that includes filing for patent extensions,...
Why Data, Trust, and Skills Are the Foundations of AI-Driven Pharmacoviginlance
Beena Wood, chief product officer at Qinecsa, argues that AI can revolutionize pharmacovigilance by detecting safety signals within hours across languages and geographies, but only if foundational data issues are solved. She highlights fragmented, non‑interoperable datasets as the primary barrier,...
Boltz PBC Launches with $28M to Democratize AI Platforms for Drug Discovery
Boltz, a public benefit corporation founded by MIT CSAIL researchers, announced a $28 million seed round led by Amplify, a16z and Zetta Venture Partners. The company aims to democratize AI‑driven drug discovery by offering Boltz Lab, an end‑to‑end platform that reduces...
Commercially Viable Biomanufacturing: Designer Yeast Turns Sugar Into Lucrative Chemical 3-HP
Scientists at the University of Illinois and Penn State have engineered the acid‑tolerant yeast *Issatchenkia orientalis* to convert plant sugars into 3‑hydroxypropionic acid (3‑HP) at commercial‑grade yields and titers. The strain achieved a 0.7 g 3‑HP per g glucose yield and 92 g 3‑HP...
Aragen Launches CHOMax Cell Line Development and Manufacturing Platform
Aragen Biologics introduced CHOMax, an integrated cell line development and early manufacturing platform for standard IgG monoclonal antibodies. Refined across more than 200 CHO programs, the platform combines cell line creation, process development, analytics, and GMP manufacturing to move projects...
Personalized Medicine Vs. Precision Medicine
Dr. Jennifer Levin Carter of Medzown clarified the distinction between personalized medicine, which tailors care to individual circumstances, and precision medicine, which leverages genetic and molecular data to design disease‑specific therapies. She highlighted oncology’s 15‑year transformation through genomics, enabling targeted...
Proteomics at Scale: Current Approaches and Emerging Technologies
The new eBook "Proteomics at Scale" examines how emerging and traditional proteomics platforms balance protein coverage with analytical detail. It highlights the inherent trade‑offs between detecting a broad protein repertoire and accurately quantifying proteoforms. The publication introduces Nautilus™’ Iterative Mapping...
BIO Investment Council Will Bring Together VC and Small Biotechs to Boost Innovation
The Biotechnology Innovation Organization (BIO) launched the BIO Investment Council (BIC) on Jan. 7 to bridge venture capital and small‑to‑mid‑size biotech firms. BIC aims to align early‑stage companies with the right investors as clinical‑stage funding now outpaces preclinical for the first...
Parkinson’s Outcomes Compared: With Vs. Without Deep Brain Stimulation
A recent comparative study evaluated Parkinson’s patients receiving deep brain stimulation (DBS) against those managed with medication alone. The analysis found that DBS recipients experienced a 40% reduction in OFF‑time and a 30% decrease in levodopa dosage, while motor scores...
Low Muscle Mass, Orthostatic Hypotension Linked in Parkinson’s
A recent multi‑center study of 200 Parkinson’s disease patients reveals that low skeletal muscle mass is strongly associated with orthostatic hypotension. Researchers found that 45% of participants with sarcopenia experienced significant blood‑pressure drops upon standing, compared with only 20% of...
New Edible Film From Fish Waste Redefines Packaging
A research team has developed an edible film made from fish processing waste, turning discarded collagen and gelatin into a thin, biodegradable packaging material. The film dissolves in water within weeks, offering a direct alternative to single‑use plastics for food...
Orca Adds $250M in Financing to Back Launch of T Cell Therapy
Orca Bio announced it has raised $250 million in new financing to support the commercial launch of its T‑cell therapy designed to treat complications from allogeneic stem cell transplants. The capital infusion comes from a mix of venture capital firms and...
GRIm Score Predicts Nivolumab Efficacy in Melanoma
A recent multicenter trial found that the Glasgow Prognostic and Immune (GRIm) score reliably predicts response to nivolumab in advanced melanoma. Patients with high GRIm scores achieved a 45% objective response rate, while low‑score patients showed markedly shorter progression‑free survival....
Novartis to Build Fourth US Radiotherapy Factory in Florida
Novartis announced the construction of its fourth U.S. radiotherapy manufacturing facility, a 35,000‑square‑foot plant in Winter Garden, Florida. The new site is part of the company’s broader $23 billion pledge to expand domestic production across the United States. The factory will...
Tuina Vs. Physiotherapy: Pain Management in Chronic Back Pain
A new comparative review examines Tuina massage versus conventional physiotherapy for chronic back pain management. The analysis cites recent randomized trials indicating both modalities achieve similar reductions in pain intensity for mild-to-moderate cases. Tuina’s manual pressure and meridian focus contrast...
Smart Leggings Boost Muscle Strength in Seniors
A biotech startup unveiled smart leggings embedded with low‑level electrical stimulation and motion sensors that claim to increase muscle strength in adults over 65. In a 12‑week clinical trial, participants wearing the leggings improved grip strength by 15% and leg...
BioNTech, UPenn Team up for $50M Seed Fund
BioNTech and the University of Pennsylvania have announced a $50 million seed‑stage venture fund focused on mRNA‑based technologies. The fund will invest in early‑stage biotech startups, leveraging BioNTech’s commercial expertise and UPenn’s research capabilities. By targeting vaccine and therapeutic platforms, the...
Single-Cell Tests Predict Mycobacterial Infection Outcomes
A new study demonstrates that single‑cell transcriptional profiling can accurately predict outcomes of mycobacterial infections, distinguishing patients who will progress to active disease from those who remain latent. Researchers analyzed thousands of individual immune cells from blood samples, identifying distinct...
MTHFD2: Key to DNA Repair and LUAD Resistance
Researchers have identified the mitochondrial enzyme MTHFD2 as a pivotal driver of DNA repair mechanisms that enable lung adenocarcinoma (LUAD) cells to survive chemotherapy and targeted therapies. Experimental knockdown of MTHFD2 reduces homologous recombination efficiency and sensitizes tumors to platinum‑based...
System Can Diagnose Infections in 20 Minutes, Aiding Fight Against Drug Resistance
Researchers from the UK and China unveiled AutoEnricher, a microfluidic‑Raman platform that identifies bacterial and fungal pathogens in just 20 minutes. Validated on 305 patient samples, the system achieved 95 % accuracy and could detect mixed infections missed by conventional cultures....
The Benefits of an Immune-Directed ADC Strategy
Lifordi Immunotherapeutics is pursuing an immune‑directed antibody‑drug conjugate (ADC) strategy that uses the VISTA protein to deliver potent steroids directly to immune cells. VISTA’s rapid internalization allows the ADC to release its payload intracellularly, aiming to avoid the systemic toxicities...
Krystal Biotech Says It Can Deliver Native Protein to Cystic Fibrosis Patients
Krystal Biotech announced early data showing its mutation‑agnostic platform can deliver functional native CFTR protein to the lungs of cystic fibrosis patients. In pre‑clinical models, the therapy restored up to 45% of normal chloride transport and reduced inflammatory markers. The...
Insmed Jumps on ‘Blowout’ Sales Beat for Bronchiectasis Drug Brinsupri
Insmed reported that its newly approved bronchiectasis therapy Brinsupri generated $144.6 million in Q4 2025 sales, nearly three times analyst forecasts. The surge was driven by roughly 9,000 new patients, bringing total users to about 11,500 and pushing the stock up 8%....
J&J Strikes Drug Pricing, Tariff Deal with the White House
Johnson & Johnson has become the latest pharmaceutical company to sign a "most‑favored‑nation" pricing agreement with the White House. The deal commits J&J to lower the list prices of a portfolio of high‑cost drugs for federal programs, including Medicare and...
Roche Spends $570M on Another ADC Agreement With China’s MediLink
Roche has agreed to pay $570 million in upfront and near‑term milestone fees to secure exclusive worldwide rights—except mainland China, Hong Kong and Macau—to MediLink’s B7H3‑targeted antibody‑drug conjugate YL201. The ADC, which carries a camptothecin‑derived cytotoxin, is advancing in registrational studies for...
J&J Jumps on the MFN Pricing Train
Johnson & Johnson has become the latest pharmaceutical company to sign a Most‑Favoured Nation (MFN) drug‑pricing agreement with the Trump administration, securing an exemption from looming tariffs. The deal, the 15th of its kind, will make J&J medicines available through...
Rampart Closes Down Less Than 2 Years After Launch
Rampart Bioscience, a stealth startup that raised $85 million in a Series A round to develop a non‑viral DNA‑based therapy platform called HALO, has shut down less than two years after emerging from stealth. The company’s website and LinkedIn page have been...
The 4x Rule: Why some People’s DNA Is More Unstable than Others
Researchers analyzed nearly one million genomes and found that short DNA repeats steadily lengthen with age. Inherited genetic variants can accelerate or decelerate this expansion by up to four‑fold, creating substantial individual differences. The study uncovered a previously unknown repeat...
InflaRx Stanches Spending With 30% Staff Reduction, Priority Pivot
InflaRx announced a restructuring that will eliminate roughly 30% of its workforce and incur about $7 million in one‑time, largely non‑cash, costs. The company is pulling funding from its COVID‑19 antibody Gohibic and redirecting resources toward izicopan, an oral C5a‑receptor inhibitor...
Roche Returns to Chinese Biotech MediLink for Another ADC Pact
Roche has entered a second licensing agreement with Chinese biotech MediLink, this time to develop an antibody‑drug conjugate (ADC) that targets the B7‑H3 antigen on solid tumours. The deal builds on a prior partnership focused on earlier‑stage oncology assets and...
AirNexis Gets $200M to Test China-Derived COPD Drug
AirNexis, a Palo Alto biotech, announced a $200 million financing round to launch clinical testing of a chronic obstructive pulmonary disease (COPD) therapy derived from Chinese research. The capital, sourced from a mix of U.S. and Chinese investors, will fund Phase 2/3...
Cellares and City of Hope Sign Deal to Automate Solid Tumor CAR T Cell Therapy Manufacturing
Biotech firm Cellares and cancer research center City of Hope have entered a partnership to evaluate Cellares’ automated Cell Shuttle manufacturing platform and Cell Q quality‑control system for City of Hope’s investigational CARpool IL13RA2‑EGFR CAR‑T therapy targeting glioblastoma multiforme. The...
Speculation Builds About a Deal for Revolution Medicines
Speculation is mounting that Revolution Medicines, a mid‑stage biotech focused on precision oncology, is in advanced talks with one or more large pharmaceutical companies. Media outlets report that the discussions could lead to a takeover or strategic partnership, though no...
Enliven’s Phase 1 Leukemia Pill Data Look Competitive with Novartis and Terns
Enliven Therapeutics announced Phase 1 results for its oral leukemia candidate, showing response rates and safety comparable to leading therapies from Novartis and Terns. The data revealed a 45% overall remission rate and manageable adverse events across 30 patients. The...
Viking Gets Commercial Chief While Other Obesity Biotechs Sell; Novo's Uli Stilz Steps Down
Viking Therapeutics announced the appointment of Neil Aubuchon as its chief commercial officer, signaling a push to accelerate commercialization of its obesity and MASH drug candidates. The move comes as the company’s shareholders grow impatient for a strategic partner or...
Evaluating Sarcopenia Criteria for Fall Prediction in Seniors
A recent cohort study examined multiple sarcopenia diagnostic criteria to determine which best predicts falls among seniors aged 65 and older. Researchers compared the European Working Group on Sarcopenia in Older People (EWGSOP2) algorithm, the SARC‑F questionnaire, and simple performance...
Mapping Prenatal Microbial Diversity in Amniotic Fluid
A new study has produced the first comprehensive map of microbial diversity in amniotic fluid, challenging the long‑held belief that the intrauterine environment is sterile. Researchers analyzed over 500 samples using ultra‑sensitive metagenomic sequencing, identifying a low‑biomass but distinct bacterial...
Gene Editing Pioneers Launch First Startup Focused on Custom CRISPR Therapies
A team of leading gene‑editing scientists has launched a new startup dedicated to developing custom CRISPR therapies for individual patients. The company builds on a landmark case last spring where researchers engineered a bespoke CRISPR treatment to correct a rare...
A New CRISPR Startup Is Betting Regulators Will Ease up on Gene-Editing
A new CRISPR startup, Aurora Therapeutics, aims to secure regulatory approval for a single, modular gene‑editing platform that can be tweaked for multiple mutations. Backed by $16 million from Menlo Ventures and advised by CRISPR co‑inventor Jennifer Doudna, Aurora’s first target...
Report Says MSD Is in Talks to Buy Revolution Meds
Financial Times reports MSD is in advanced talks to acquire Revolution Medicines in a deal valued between $28 billion and $32 billion, potentially the largest pharma merger since Pfizer's Seagen purchase. The announcement sent Revolution’s shares up 16% in pre‑market trading, giving...
Study Finds Food Waste Compost Less Effective than Potting Mix Alone
Researchers at the University of Arkansas evaluated food‑waste compost as a growing substrate for tomato and watermelon seedlings. The study, published in HortTechnology, found that pure food‑waste compost performed worse than standard peat‑based potting mix, while blends containing less than...
Bone Marrow Immune Cell Map Boosts Survival, Relapse Prediction in Multiple Myeloma
Researchers created a single‑cell immune atlas of bone‑marrow cells from 337 newly diagnosed multiple myeloma patients, profiling nearly 1.4 million plasma and immune cells. The study, published in Nature Cancer, links specific immune cell populations and signaling pathways to rapid relapse...